cyproterone acetate has been researched along with Prostatic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Angelo, S; Olivieri, I; Palazzi, C; Pennese, E | 1 |
| Lotti, T; Montironi, R; Polito, M; Prezioso, D | 1 |
1 trial(s) available for cyproterone acetate and Prostatic Diseases
| Article | Year |
|---|---|
Leuprorelin 1-month depot as neoadjuvant therapy for prostate cancer. Takeda NHT Italian Group.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyproterone Acetate; Delayed-Action Preparations; Diagnosis, Differential; Disease-Free Survival; Drug Administration Schedule; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatectomy; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms | 1998 |
1 other study(ies) available for cyproterone acetate and Prostatic Diseases
| Article | Year |
|---|---|
Persistent normalization of serum levels of uric acid in a gouty patient after administration of cyproterone acetate.
Topics: Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Gout; Humans; Male; Prostatic Diseases; Time Factors; Treatment Outcome; Uric Acid | 2009 |